FTH
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.79 | $0 | -$13M |
| 2026 Q2 | -2.84 | $0 | -$16M |
| 2026 Q1 | -131.45 | $0 | -$11M |
| 2025 Q4 | -3.74 | $0 | -$4M |
| 2025 Q3 | -3.62 | -$5M | -$4M |
| 2025 Q2 | -3.91 | $0 | -$6M |
| 2025 Q1 |
| -5.45 |
| $0 |
| -$7M |
| 2024 Q4 | -6.18 | $0 | -$6M |